liposomal amphotericin B + posaconazole + isavuconazole

This combination therapy involves the co-administration of liposomal amphotericin B (L-AmB) with the triazole antifungals posaconazole and/or isavuconazole. Liposomal amphotericin B is a polyene antifungal that acts by binding to ergosterol in fungal cell membranes, creating pores that lead to cell death; the liposomal formulation is designed to reduce systemic toxicity, particularly nephrotoxicity. Posaconazole and isavuconazole are second-generation triazoles that inhibit the enzyme lanosterol 14α-demethylase (CYP51), thereby blocking the biosynthesis of ergosterol, an essential component of the fungal cell membrane. This multi-drug regimen is being evaluated by the Institute of Hematology & Blood Diseases Hospital in China for the treatment of mucormycosis in adult patients with hematologic malignancies. The strategy aims to improve clinical outcomes in this high-risk population by leveraging potential synergistic antifungal activity and providing a transition path from intravenous to oral therapy.

Other names

L-AmB + posaconazole + isavuconazole